News
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Bausch Health and Salix Pharmaceuticals provide updates on litigation with Norwich Pharmaceuticals and potential generic version of XIFAXAN. Bausch Health to enforce intellectual property rights. Details on FDA approval process and patent infringement lawsuit -
COMMUNIQUÉ DE PRESSE
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN -
COMMUNIQUÉ DE PRESSE
NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois
Nanobiotix annonce l'acceptation par la FDA d'un protocole pour une nouvelle étude de phase 2 sur NBTXR3 pour le cancer du poumon de stade III -
-
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website -
-
COMMUNIQUÉ DE PRESSE
Hamilton Health Box Raises $10 Million in Series A Funding to Accelerate Rural Market Expansion
Hamilton Health Box secures $10M Series A funding to expand into rural America, addressing Health Professional Shortage Areas. The unique microclinic model offers affordable primary care services
